An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

NCT03911869 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
13
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated due to lack of enrollment of the target population. There were no safety, efficacy, or regulatory interaction involved in the decision to stop enrollment.

Conditions

Interventions

Sponsor

Pfizer